ReviewClinical microbiology reviews2017
Chromoblastomycosis.
Review in Clinical microbiology reviews, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 168 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
168 citing papers in PubMed, 3 syntheses or guidelines pooled it, 323 citations in OpenAlex.
- The global burden of chromoblastomycosis.PLoS neglected tropical diseases · 2021Pooled it
- Pyoderma gangrenosum: a review with special emphasis on Latin America literature.Anais brasileiros de dermatologiaPooled it
- Accuracy of direct examination and culture as compared to the anatomopathological examination for the diagnosis of chromoblastomycosis: a systematic review.Anais brasileiros de dermatologiaPooled it
- From molecular advances to limited clinical impact: The persistent gap in chromoblastomycosis.PLoS neglected tropical diseases · 2026Review
- Molecular Evidence of Autochthonous Environmental Acquisition ofOpen forum infectious diseases · 2026Article
- Multimodal skin imaging in chromoblastomycosis: Diagnostic correlation and treatment monitoring during adjunctive fractional carbon dioxide laser therapy.JAAD case reports · 2026Article
- Chromoblastomycosis caused by Phialophora macrospora.Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG · 2026Article
- Establishment of epidemiological cutoff values againstJournal of clinical microbiology · 2026Article
- Article
- Photo Quiz: Brown, thick-walled cells with evident septation in a purulent sample from a mason.Journal of clinical microbiology · 2026Article
- Contribution of fungal diseases to the U.S. chronic disease burden.Clinical microbiology reviews · 2026Review
- Implantation mycoses: A nationwide survey on diagnostic and treatment modalities in Nepal.PLoS neglected tropical diseases · 2026Article
- Article
- Antifungal activity of the antimicrobial peptide RP557 against priority fungal pathogens.Microbiology (Reading, England) · 2026Article
- In Vitro Activities of Five Antifungal Drugs Against Conidia and Sclerotic Cells of Chromoblastomycosis Agent Fonsecaea spp.Microbiology and immunology · 2026Article
- Sequential Phialemoniopsis curvata and Botryosphaeria dothidea infections over three years in bilateral lower limbs of a rheumatoid arthritis patient: a case-based review.BMC infectious diseases · 2026Review
- Impaired NLRP3 inflammasome activation by chitin underlies refractory chromoblastomycosis caused byFrontiers in immunology · 2026Article
- Article
- Time-resolved multi-omics reveals macrophage-centered immunometabolic remodeling in cutaneous dematiaceous fungal infection.Frontiers in immunology · 2026Article
- Single-cell RNA sequencing unravels T cell exhaustion underlying the chronicity of chromoblastomycosis.Frontiers in immunology · 2026Article
108 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 10 institutions in 6 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chromoblastomycosis (CBM), also known as chromomycosis, is one of the most prevalent implantation fungal infections, being the most common of the gamut of mycoses caused by melanized or brown-pigmented fungi. CBM is mainly a tropical or subtropical disease that may affect individuals with certain risk factors around the world. The following characteristics are associated with this disease: (i) traumatic inoculation by implantation from an environmental source, leading to an initial cutaneous lesion at the inoculation site; (ii) chronic and progressive cutaneous and subcutaneous tissular involvement associated with fibrotic and granulomatous reactions associated with microabscesses and often with tissue proliferation; (iii) a nonprotective T helper type 2 (Th2) immune response with ineffective humoral involvement; and (iv) the presence of muriform (sclerotic) cells embedded in the affected tissue. CBM lesions are clinically polymorphic and are commonly misdiagnosed as various other infectious and noninfectious diseases. In its more severe clinical forms, CBM may cause an incapacity for labor due to fibrotic sequelae and also due to a series of clinical complications, and if not recognized at an early stage, this disease can be refractory to antifungal therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.